Formulation Development Services for Lipid & Polymer Nanoparticles
Product Description
Curapath
-
Country/Region:Spain
-
On CPHI since:2023
-
Certificates:1
-
Employees:50 - 99
Company types
Primary activities
Categories
Curapath
-
Country/Region:Spain
-
On CPHI since:2023
-
Certificates:1
-
Employees:50 - 99
Company types
Primary activities
More Products from Curapath (8)
-
Product Bioconjugation
Polymer bioconjugation offers powerful strategies to extend half-life, improve stability, and enable encapsulation of therapeutic molecules. By conjugating polymers to proteins, peptides, or other actives, it is possible to enhance pharmacokinetics, reduce immunogenicity, and unlock new delivery pathways. ... -
Product Custom polymers and lipids
Custom polymers and lipids enable the creation of tailored delivery systems that meet the unique requirements of each therapeutic program. At Curapath, we support our partners with bespoke synthesis and design, offering flexibility in polymer architecture, lipid structures, functionalization, and scale. Th... -
Product ionizable lipids
Ionizable lipids are key components in LNP formulations, enabling efficient RNA encapsulation and protection, while ensuring intracellular release through their pH-dependent charge switch. This unique property makes them essential for the safe and effective delivery of nucleic acid-based therapeutics. At ... -
Product Ready-to-use formulations
Ready-to-use formulations simplify development by providing immediate access to well-characterized LNP systems. At Curapath, we offer a spectrum ranging from standard reference formulations to custom-designed systems, where we combine our proprietary shielding lipids with innovative ionizable lipids. This ... -
Product Shielding lipids
Shielding lipids play a crucial role in prolonging circulation time and enhancing the stability of LNPs by preventing opsonization and rapid clearance. Traditionally, PEG-lipids have been used for this purpose, but concerns around immunogenicity and tolerability have driven the search for better solutions.... -
Product PEG-Free Shielding Lipids
Shielding lipids are key to keeping LNPs stable, long‑circulating, and efficient at delivering RNA or gene‑therapy payloads. As PEG‑based systems face growing concerns due to immunogenicity and accelerated clearance, new PEG‑free strategies are becoming essential for safer and more flexible nanoparticle de... -
Product PSar‑based solubilizing agent
Biologic formulations often struggle with protein aggregation, immunogenicity, and limited shelf life, while polysorbates can degrade in aqueous environments and trigger PEG‑related reactions; PSar‑based solubilizing agents offer a next‑generation alternative that improves stability, enhances solubility at... -
Product Solutions for PLA/PLGA API Encapsulation
Curapath introduces a structured suite of Formulation Development Packages designed to streamline the creation and optimization of PLA/PLGA‑based nanoparticles for peptides and small molecules, offering three scalable levels of support: the Essential package focuses on rapid development of PLA/PLGA + API n...
Curapath resources (10)
-
Brochure Product Catalog
Discover Curapath's cutting-edge offerings in our catalog. Explore our LNP and PNP components, as well as our polymer conjugates, all designed to advance drug delivery. Enhance your research and development with our high-quality products.Advanced Polymer & Lipid Solutions for Non-Viral Drug DeliveryPEG-free excipients, transfection reagents, and polymer platforms for next-generation therapeutics -
Brochure Active Targeting Shielding Lipids for Targeted LNP Delivery
Targeted LNP Shielding Lipids (PEG-Free) | CliCr® Conjugation | CurapathEngineered PEG-free polysarcosine lipids modified with CliCr® conjugation technology to enable precise ligand attachment and extrahepatic LNP targeting.Explore our Active Targeting Shielding Lipids catalog, a curated selection of PEG-free polysarcosine lipids engineered for precise ligand conjugation and extrahepatic LNP delivery.
-
Brochure CDMO Services for Advanced Drug Delivery (LNPs, PNPs & Polymers)
From early formulation development to GMP manufacturing and aseptic Fill & Finish, supporting innovative therapeutics from preclinical to commercial supply.Explore Our Complete CDMO CapabilitiesExplore our CDMO Services overview, outlining our integrated approach to advanced lipid and polymer-based drug delivery, from early development to GMP manufacturing and aseptic Fill & Finish.
-
Brochure Formulation Development Packages for LNP & PNP
Curapath has launched a tiered suite of Formulation Development Packages to accelerate the design and optimization of Lipid Nanoparticle (LNP) and Polymer Nanoparticle (PNP) systems for nucleic acid and peptide delivery. These packages, Essential, Advanced, and Expert, are built to offer increasing levels of complexity, analytical depth, and formulation flexibility. -
Brochure Formulation Development Packages for PLA/PLGA Nanoparticles
Curapath introduces a structured suite of Formulation Development Packages, designed to streamline the creation and optimization of PLA/PLGA-based nanoparticles for the encapsulation of peptides and small molecules. -
Brochure Next generation LNPs formulation with Curapath’s excipients
Curapath and Certest have teamed up to develop next-generation Lipid Nanoparticle (LNP) formulations for nucleic acid-based therapeutics. This novel formulation combines Curapath's PEG-alternative shielding lipid with Certest's enhanced ionizable lipid, addressing challenges like immune-related side effects and reduced efficacy of PEG-based systems. This collaboration aims to improve stability, efficiency, and the versatility of payload delivery in advanced therapies.. Learn more about this cutting-edge combination of technologies by accessing the full document.. -
Brochure Polymer-Drug Conjugates Case Study
A biotech company developing a polymer-drug conjugate (PDC) for parenteral use needed a partner to support their transition to clinical trials. They required expertise in process development, scale-up, and GMP-compliant manufacturing. Curapath met these needs with a comprehensive approach, ensuring efficiency and quality at every stage. Learn more about how Curapath met the needs of this client by accessing the full document.. -
Whitepaper Psar based solubilizing agent for second generation biologics
Our PolySarcosine based solution for biologics (Available for mAbs, recombinant vaccines, peptides, and hormones.) improves both Stability and Solubility outperforming current solutions like polysorbates without compromising safety. -
Brochure LNP Analytical Methods Application
Discover our cutting-edge capabilities for lipid nanoparticle characterization, alongside our meticulous in-process controls integrated into lipid nanoparticle formulations. Elevate your understanding of nanomedicine with our comprehensive insights. Download now to unlock the future of nanoparticle analysis. -
Brochure LNP Formulation & Process Development Application Note
LNP Formulation & Process Development Application Note! the sensitivity of LNPs for manufacturing and purification processes necessitates the development of a robust and scalable approach. This application note provides insight into Curapath's endeavor to achieve a GMP-compliant LNP formulation, demonstrating the critical path taken to ensure the production of clinically accepted drug products. Download now to understand the scalable manufacturing capabilities of Curapath.